The effectiveness of novel oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during predominance of omicron XBB subvariants

CONCLUSION: The use of novel oral antiviral including NMV-r or MOV can be associated with a lower risk of all-cause hospitalization, or death in non-hospitalized high-risk patients with COVID-19 during Omicron XBB wave.PMID:38568820 | DOI:10.1080/14787210.2024.2339398

Source: Expert Review of Anti-Infective Therapy - April 3, 2024 Category: Infectious Diseases Authors: Chi-Kuei Hsu Wan-Hsuan Hsu Bo-Wen Shiau Ya-Wen Tsai Jheng-Yan Wu Ting-Hui Liu Po-Yu Huang Min-Hsiang Chuang Chih-Cheng Lai Source Type: research